Bortezomib-Based Versus Nonbortezomib-Based Induction Treatment Before Autologous Stem-Cell Transplantation in Patients With Previously Untreated Multiple Myeloma: A Meta-Analysis of Phase III Randomized, Controlled Trials
Journal of Clinical Oncology2013Vol. 31(26), pp. 3279–3287
Citations Over TimeTop 1% of 2013 papers
Pieter Sonneveld, Hartmut Goldschmidt, Laura Rosiñol, Joan Bladé, Juan José Lahuerta, Michèle Cavo, Paola Tacchetti, Elena Zamagni, Michel Attal, Henk M. Lokhorst, Avinash Desai, Andrew Cakana, Kevin Liu, Helgi van de Velde, Dixie‐Lee Esseltine, Philippe Moreau
Abstract
Bortezomib-based induction results in significant improvements in response and PFS/OS compared with nonbortezomib-based induction and is generally well tolerated, with a higher rate of peripheral neuropathy but no apparent increase in risk of death during induction.
Related Papers
- Therapeutic effect of small dose thalidomide and dexamethasone for old multiple myeloma(MM) patients(2009)
- The Clinical Effectiveness Of Thalidomide Combined With Low Dose Dexamethasone On Multiple Myeloma(2010)
- Clinical Observation of the Combination of Thalidomide and Dexamethasone for the Treatmemt of Recurrent Multiple Myeloma(2009)
- Clinical observation on the thalidomide combined with the dexamethasone in treatment of multiple myeloma(2008)
- Thalidomide combined with MP and VAD in the treatment of multiple myeloma for 42 cases(2010)